Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Reform: Senate May Amend Two Provisions In House Bill

Executive Summary

The Senate will vote on whether to limit debate on the House-passed patent reform bill when it reconvenes on Sept. 6. Senate Majority Leader Harry Reid, D-Nev., made a motion for the cloture vote before the August recess in hopes of getting a final bill through Congress quickly.

You may also be interested in...



Drug Importation Is A High-Profile Addition To US FDA’s Regulatory Agenda

Agency is targeting January 2020 for release of controversial proposed rule to allow importation of certain types of prescription drugs from Canada; although most Rx drug-related proposed and final rules on the Fall 2019 regulatory agenda are making repeat appearances, a final rule on electronic distribution of prescribing information has fallen off the list.

It's All Over But The Signing: Patent Reform Bill Passes Senate Without Amendments

Senate tables an amendment that would have scuttled the House compromise on PTO fee diversion, keeps intact provision extending time to file for patent term extension.

It's All Over But The Signing: Patent Reform Bill Passes Senate Without Amendments

Senate tables an amendment that would have scuttled the House compromise on PTO fee diversion, keeps intact provision extending time to file for patent term extension.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel